World Pharma Today

A new study has discovered how hepatitis C virus survives in the liver – helping medical scientists understand why a new antiviral drug appears to be effective against the virus.

Add new comment

Eating disorders harm women's fertility

Eating disorders affect approximately seven million American women each year and tend to peak during childbearing years.

Add new comment

Ovarian cancer study proves drug delays disease progression

Drs. Amit Oza of the Princess Margaret Cancer Program, University Health Network and Timothy Perren, St James's Institute of Oncology, Leeds, UK, show the results of an international clinical trial, Treating ovarian cancer with the drug bevacizumab (... Read more...

Benefits of statin therapy may extend beyond lowering lipids

People with high cholesterol are at risk of heart attack and stroke because atherosclerotic plaques within their arteries can rupture triggering the formation ...

Treating Cancer with Light

New LED Device May Help Advance Photodynamic Therapy for Skin Cancer. Scientists at the University of California, Irvine (UC Irvine), believe so. They're explo...

Exploring Opportunities in Chemical Biology

Interview with: Torsten Hoffmann, Head Discovery Chemistry, F. Hoffmann – La Roche
Drug discovery scientists need to broaden their approaches to pharmaceutical...

Knowledge Bank

Edit

News Press Releases Research Insight Techno Trends Industry Reports Articles

Amount of short articles:

Amount of articles links:

You can order sections with dragging on list bellow:

Knowledge Bank
Business & Industry

Save

Cancel

Reset

News

Roche Signs Licensing Agreement with Sysmex Inostics GmbH for emPCR Patent

Pleasanton, CA, USA, 21 February 2014 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a licensing agreement with Sysmex Inostics GmbH for its emPCR portfolio of patents. Under the

Friday, 21 February 2014 Comments

Press Releases

Adocia announces preliminary positive clinical results for its combination of long-acting insulin Glargine and fast-acting insulin analog Lispro, Biochaperone(R) C

Adocia’s BioChaperone Combo is the first product combining insulin Glargine with a fast-acting insulin analogPhase I/II clinical trial demonstrates proof of concept in patients with type 1 diabetes, showing that

Friday, 28 February 2014 Comments

Research Insight

Body kills 'spontaneous' blood cancers on a daily

Immune cells undergo 'spontaneous' changes on a daily basis that could lead to cancers if not for the diligent surveillance of our immune system, Melbourne scientists have found. The research

Monday, 3 February 2014 Comments

Techno Trends

Amgen, MGH, Broad Institute to discover new drugs to treat inflammatory bowel

Amgen (AMGN), Massachusetts General Hospital (MGH) and the Broad Institute have entered inot a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory

Friday, 17 January 2014 Comments

Industry Reports

Adocia: annual revenue of EUR 5.6 M in

Adocia , a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic molecules, in particular proteins and oncologic drugs, announces today its revenue for the last

Wednesday, 19 February 2014 Comments

Articles

Oncology Treatment Adherence: Understanding the Patient

It would be easy to assume that an oral treatment that can halt the progression of a rare form of leukaemia would have high rates of adherence.

Tuesday, 14 August 2012 Comments

Business & Industry